secwatch.observer — SEC 8-K summary
======================================

Issuer:     PAVmed Inc. (PAVM)
CIK:        0001624326
Form:       8-K
Filed at:   2026-08-14T14:44:53+00:00
Accession:  0001493152-26-038072
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PAVmed Q2 2026 net loss $5.5M; Lucid EsoGuard revenue $1.5M, cash up to $3.8M
-----------------------------------------------------------------------------

- Q2 2026 GAAP net loss ~$5.5M ($0.87/diluted share); non-GAAP adjusted net loss ~$1.7M ($0.27/share).
- Cash and equivalents $3.8M at June 30, 2026, up from $1.5M at Dec 31, 2025; operating expenses ~$7.1M.
- Lucid Diagnostics (LUCD) posted $1.5M EsoGuard revenue in 2Q26, 2,770 tests; secured first lab benefit manager coverage policy.
- Veris Health accelerated commercial engagement with OSU-The James; implantable monitor on track for early 2027 FDA 510(k) submission.
- PortIO first-in-human data published in Journal of Vascular Access: 100% patency, 90% intended implant duration completion, no device-related adverse events.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1624326/000149315226038072/0001493152-26-038072-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1624326/000149315226038072/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-038072

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer